| TRPM7 regulates gastrulation during vertebrate embryogenesis W Liu, LT Su, DK Khadka, C Mezzacappa, Y Komiya, A Sato, R Habas, ... Developmental biology 350 (2), 348-357, 2011 | 88 | 2011 |
| Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies N Dedic, H Dworak, C Zeni, G Rutigliano, OD Howes International Journal of Molecular Sciences 22 (24), 13185, 2021 | 67 | 2021 |
| MIM regulates vertebrate neural tube closure W Liu, Y Komiya, C Mezzacappa, DK Khadka, L Runnels, R Habas Development 138 (10), 2035-2047, 2011 | 38 | 2011 |
| Patches: established and emerging transdermal treatments in psychiatry L Citrome, CM Zeni, CU Correll The Journal of clinical psychiatry 80 (4), 21174, 2019 | 37 | 2019 |
| Activation and function of small GTPases Rho, Rac, and Cdc42 during gastrulation C Mezzacappa, Y Komiya, R Habas Planar Cell Polarity: Methods and Protocols, 119-131, 2012 | 29 | 2012 |
| Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia ED Achtyes, SC Hopkins, N Dedic, H Dworak, C Zeni, K Koblan European Archives of Psychiatry and Clinical Neuroscience 273 (7), 1543-1556, 2023 | 18 | 2023 |
| Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study L Citrome, DP Walling, CM Zeni, BR Starling, T Terahara, M Kuriki, ... The Journal of clinical psychiatry 82 (1), 1417, 2020 | 18 | 2020 |
| Hepatocystin is essential for TRPM7 function during early embryogenesis JD Overton, Y Komiya, C Mezzacappa, K Nama, N Cai, L Lou, SV Fedeles, ... Scientific reports 5 (1), 18395, 2015 | 10 | 2015 |
| A nonredundant role for the TRPM6 channel in neural tube closure Y Komiya, Z Bai, N Cai, L Lou, N Al-Saadi, C Mezzacappa, R Habas, ... Scientific reports 7 (1), 15623, 2017 | 8 | 2017 |
| Challenges in the clinical development of non-D2 compounds for schizophrenia SC Hopkins, R Lew, C Zeni, KS Koblan Current Medical Research and Opinion 39 (3), 467-471, 2023 | 6 | 2023 |
| Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by … SC Hopkins, A Ogirala, C Zeni, MA Worden, KS Koblan Clinical Drug Investigation 42 (12), 1113-1121, 2022 | 5 | 2022 |
| Efficacy and Safety of an Asenapine Transdermal Patch (Asenapine Transdermal System, HP-3070) in the Treatment of Adults with Schizophrenia: A Phase 3, Randomized, Double-Blind … L Citrome, D Walling, C Zeni, M Komaroff, A Park | 5 | 2019 |
| Blonanserin patch vs. other antipsychotics for acute schizophrenia: a systematic review of double-blind, randomized, placebo-controlled, phase 3 trials in Japan T Kishi, R Yoshimura, Y Matsuda, K Sakuma, N Iwata Pharmacopsychiatry 53 (03), 122-132, 2020 | 2 | 2020 |
| 146 Efficacy and safety of the asenapine transdermal patch, HP-3070, for schizophrenia: A Phase 3, randomized, placebo-controlled, inpatient study L Citrome, D Walling, C Zeni, M Komaroff, A Park CNS spectrums 25 (2), 293-293, 2020 | 2 | 2020 |
| Patches L Citrome, CM Zeni, CU Correll The Journal of Clinical Psychiatry 80 (4), 2019 | 2 | 2019 |
| O50. Efficacy and safety of an asenapine transdermal patch (asenapine transdermal system, HP-3070) in the treatment of adults with schizophrenia: a phase 3, randomized, double … L Citrome, D Walling, C Zeni, M Komaroff, A Park Biological Psychiatry 85 (10), S126, 2019 | 2 | 2019 |
| TAAR1 Agonist Ulotaront Improves Glycemic Control and Reduces Body Weight in Rodent Models of Diabetes, Obesity, and Iatrogenic Weight Gain N Dedic, PG Jones, E Hajos-Korcsok, C Synan, S Wu, C Anacker, ... CNS Spectrums 28 (2), 259-259, 2023 | 1 | 2023 |
| Ulotaront improves metabolic parameters in rodent models of weight gain and hyperglycemia C Zeni, N Dedic, P Jones, S Wu, C Anacker, E Hajos-Korcsok | 1 | 2022 |
| Assessing the benefit-risk ratio of approved treatments for bipolar depression using likelihood to be helped or harmed (LHH) analyses L Citrome, M Tocco, C Zeni, A Pikalov, R Goldman CNS spectrums 26 (2), 146-146, 2021 | 1 | 2021 |
| P. 323 Assessing the benefit-risk ratio of approved treatments for bipolar depression using likelihood to be helped or harmed (LHH) analyses L Citrome, M Tocco, C Zeni, A Pikalov, R Goldman European Neuropsychopharmacology 40, S187, 2020 | 1 | 2020 |
RAYMOND HABASTemple University在 temple.edu 的电子邮件经过验证
